Bard Indrevall

Title: Bard Indrevall: Innovator in Radiotracer Compositions

Introduction

Bard Indrevall is a notable inventor based in Oslo, Norway. He has made significant contributions to the field of medical imaging, particularly through his innovative work on peptide radiotracer compositions. His research focuses on enhancing the capabilities of positron emission tomography (PET) imaging, which is crucial for cancer management.

Latest Patents

Bard Indrevall holds a patent for his invention titled "Peptide radiotracer compositions." This invention relates to imaging agent compositions that comprise radiolabelled c-Met binding peptides suitable for in vivo PET imaging. The c-Met binding peptides are labelled with the radioisotope F. The patent also discloses pharmaceutical compositions, methods of preparation for the agents and compositions, as well as methods for in vivo imaging using these compositions, particularly in the context of cancer management. He has 1 patent to his name.

Career Highlights

Bard Indrevall is associated with GE Healthcare Limited, a company renowned for its advancements in medical technology and imaging solutions. His work at GE Healthcare has allowed him to contribute to the development of innovative imaging agents that can significantly improve diagnostic capabilities.

Collaborations

Throughout his career, Bard has collaborated with esteemed colleagues such as Peter Brian Iveson and Rajiv Bhalla. These collaborations have fostered a productive environment for innovation and have led to advancements in the field of medical imaging.

Conclusion

Bard Indrevall's contributions to the field of radiotracer compositions exemplify the importance of innovation in medical imaging. His work not only enhances diagnostic techniques but also plays a vital role in the management of cancer.